VOR — Vor Biopharma Share Price
0.000.00%
Last trade - 00:00- $238.67m
- $178.64m
- 17
- 10
- 80
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.61 | ||
| Price to Tang. Book | 3.61 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -131.93% | ||
| Return on Equity | -125.43% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Directors
- Kush Parmar NEC (40)
- Robert Ang PRE
- Nathan Jorgensen CFO (44)
- Sadik Kassim CTO (40)
- Tirtha Chakraborty CSO (48)
- Christopher Slapak OTH (62)
- Daniella Beckman IND (42)
- David Lubner IND (57)
- Sven Lundberg IND (57)
- Matthew Patterson IND (49)
- Joshua Resnick IND (46)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 30th, 2015
- Public Since
- February 5th, 2021
- No. of Shareholders
- 17
- No. of Employees
- 159
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 124,959,520
- Address
- 100 Cambridgepark Drive, Suite 101, CAMBRIDGE, 02140
- Web
- https://www.vorbio.com/
- Phone
- +1 6176556580
- Auditors
- Ernst & Young LLP
Upcoming Events for VOR
Q3 2025 Vor Biopharma Inc Earnings Release
Similar to VOR
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Vor Biopharma share price?
As of Today at 06:01 UTC, shares in Vor Biopharma are trading at $1.91. This share price information is delayed by 15 minutes.
How has the Vor Biopharma share price performed this year?
Shares in Vor Biopharma last closed at $1.91 and the price had moved by +107.61% over the past 365 days. In terms of relative price strength the Vor Biopharma share price has outperformed the S&P500 Index by +85.6% over the past year.
What are the analyst and broker recommendations for Vor Biopharma?
The overall consensus recommendation for Vor Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vor Biopharma dividend yield?
Vor Biopharma does not currently pay a dividend.
Does Vor Biopharma pay a dividend?
Vor Biopharma does not currently pay a dividend.
When does Vor Biopharma next pay dividends?
Vor Biopharma does not currently pay a dividend.
How do I buy Vor Biopharma shares?
To buy shares in Vor Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vor Biopharma?
As of the previous close price of $1.91, shares in Vor Biopharma had a market capitalisation of $238.67m.
Where are Vor Biopharma shares listed?
Here are the trading details for Vor Biopharma:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VOR
What kind of share is Vor Biopharma?
Based on an overall assessment of its quality, value and momentum Vor Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vor Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Vor Biopharma is $1.18. That is 38.22% below the last closing price of $1.91.
Analysts covering Vor Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.70 for the next financial year.
Find out moreWhat is the trend in the Vor Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vor Biopharma. Over the past six months, its share price has outperformed the S&P500 Index by +38.84%.
As of the last closing price of $1.91, shares in Vor Biopharma were trading +129.45% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vor Biopharma PE Ratio?
The Vor Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vor Biopharma?
Vor Biopharma's management team is headed by:
- Kush Parmar - NEC
- Robert Ang - PRE
- Nathan Jorgensen - CFO
- Sadik Kassim - CTO
- Tirtha Chakraborty - CSO
- Christopher Slapak - OTH
- Daniella Beckman - IND
- David Lubner - IND
- Sven Lundberg - IND
- Matthew Patterson - IND
- Joshua Resnick - IND